Malaysia-Thailand 2026 Medical Device Regulatory Reliance Pilot
The Malaysia-Thailand Medical Device Regulatory Reliance Pilot 2026 enables faster approvals for class B/C/D devices by leveraging mutual regulatory assessments. Manufacturers with devices registered in either country can benefit from shorter review timelines, waived fees, and reduced duplication. The 3-month pilot (1 Feb–30 Apr 2026) supports faster patient access to safe, innovative medical devices and may serve as a model for future ASEAN regulatory reliance initiatives.
The Malaysia-Thailand Medical Device Regulatory Reliance Pilot 2026 is a 3-month program running from 1 February to 30 April 2026, designed to streamline registration of class B/C/D (2/3/4) medical devices. By leveraging mutual regulatory assessments, the pilot reduces duplicated reviews, shortens time-to-market, lowers costs, and gives patients faster access to safe and high-quality devices. Manufacturers with prior approval in either country can take advantage of this fast-track regulatory pathway.
Strategic Importance of the Pilot
Marks a new chapter in regulatory convergence and industry cooperation between Malaysia and Thailand.
Serves as a sandbox for ASEAN member states in regulatory reliance.
Reduces duplication of regulatory assessments and accelerates device availability.
Benefits of the Malaysia-Thailand Regulatory Reliance Program
Faster approvals: Both countries rely on each other’s regulatory assessments.
Cost efficiency: Minimizes duplicated reviews and associated fees.
Improved patient access: Innovative and high-quality devices reach the market sooner.
Malaysia Registration Pathway
Eligible Devices: Class 2/3/4 medical devices registered with Thai FDA.
Review Route: Verification route (abridged pathway) via Conformity Assessment Body (CAB).
Timeline: Review in 30 working days (compared with 60 days under full route) and device registration completed within 30 working days.
Benefits: Reduces regulatory burden and accelerates market entry.
Learn more about MDA Malaysia Medical Device Registration
Thailand Registration Pathway
Eligible Devices: Class B/C/D devices registered with MDA Malaysia.
Review Route: Full submission pathway without external expert review.
Timeline: Reduced from 150 to 120 calendar days; expert review fees waived.
Benefits: Streamlines approvals and reduces costs for manufacturers.
Learn more about Thai FDA Medical Device Registration
Who Benefits Most
Devices without reference country approval (USA, EU, Canada, Australia, Japan) gain significant advantages under this pilot.
Devices already approved in reference countries do not gain additional benefits under this Reliance pathway.
Products with reference country approval older than 1 year already qualify for Thailand’s expedited pathway.
Future Reliance Programs
At the Malaysia Pharma and Healthcare Expo 2025, MDA indicated plans to explore reliance with India, Brazil, Indonesia, Pakistan, Egypt, UAE, and Turkey.
Thailand is the first confirmed pilot, but more Reliance programs may be announced later in 2026.
Duration and Limitations
A prior Malaysia-China Reliance program (30 July–30 September 2025) has no confirmed extension.
Similarly, there is no guarantee that the Malaysia-Thailand Reliance Pilot will continue after 30 April 2026.
Manufacturers with non-reference country approved devices should take advantage while the pilot is active.
Key Takeaways for Manufacturers
Streamlined approval pathways can significantly shorten time-to-market.
Cost and regulatory burden are reduced.
Early adoption is crucial due to the limited pilot duration.
Supports regional harmonization and sets a precedent for future ASEAN regulatory reliance initiatives.
External Links:
Let's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us






